Randomized, open‐label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma
Article 2016 en
Authors
AC
Ann‐Lii Cheng
ST
Sumitra Thongprasert
HL
Ho Yeong Lim
Abstract
1 min read
Dovitinib was well tolerated, but activity was not greater than sorafenib as a frontline systemic therapy for HCC. Based on these data, no subsequent phase 3 study has been planned. (Hepatology 2016;64:774-784).
Josep M. Llovet, Serafino Ricci, Vincenzo Mazzaferro, P Hilgard, Jean‐Luc Raoul, Stefan Zeuzem, Melanie Poulin-Costello, M. Moscovici, D. Voliotis, Jordi Bruix
Gontran Verset, Ivan Borbath, Mark Karwal, Chris Verslype, Hans Van Vlierberghe, Adel Kardosh, Vittorina Zagonel, Per Stål, Debashis Sarker, Daniel H. Palmer, Arndt Vogel, Julien Edeline, Stéphane Cattan, Masatoshi Kudo, Ann‐Lii Cheng, Sadahisa Ogasawara, Bruno Daniele, Stephen L. Chan, Jennifer J. Knox, Shukui Qin, Abby B. Siegel, Michael Chisamore,
Discussion(0)
No comments yet. Be the first to comment.